Elsevier

Biochemical Pharmacology

Volume 34, Issue 10, 15 May 1985, Pages 1763-1771
Biochemical Pharmacology

Drug-protein conjugates—VIII The metabolic fate of the dinitrophenyl hapten conjugated to albumin

https://doi.org/10.1016/0006-2952(85)90647-1Get rights and content

Abstract

Dinitroflorobenzene has been used as a model chemically reactive metabolite to investigate factors which determine the fate of drug-protein conjugates formed in vivo.

The disposition of homologous and heterologous albumin conjugated with 3H-dinitrophenyl groups (3H-DNP) has been investigated in the male Wistar rat. After intravenous administration, conjugates were cleared from plasma, predominantly through the liver, and the hapten was excreted into bile and urine as the novel amino acid derivative N2-acetyl-N6-DNP-lysine. It is assumed that the product arises from lysosomal hydrolysis of the conjugate, followed by N-acetylation, since its biliary excretion was significantly reduced in animals pretreated with suramin, an inhibitor proteolysis. The clearance of DNP-albumin conjugates was dependent upon the degree of conjugation; conjugates with an epitope density of > 20 had a short (ca. 1 hr) half-life.

In a second study, the disposition of DNP-autologous protein conjugates was monitored in the rabbit over 21 days. The plasma concentration-time profile of the serum conjugates indicated that clearance was dependent upon non-immune mechanisms and that intravenous administration of DNP-serum protein conjugates did not elicit an anti-DNP response.

References (31)

  • G.L. Lamoureux et al.

    Pestic. Biochem. Physiol.

    (1975)
  • O.H. Lowry et al.

    J. biol. Chem.

    (1951)
  • K. Shigesada et al.

    Biochem. biophys. Res. Commun.

    (1971)
  • S. Grisolia et al.

    Biochim. biophys. Acta

    (1962)
  • M.D. Armstrong

    Biochim. biophys. Acta

    (1979)
  • H.N. Eisen et al.

    J. Immunol.

    (1954)
  • A.L. de Weck et al.

    J. exp. Med.

    (1960)
  • J.A. Miller

    Cancer Res.

    (1970)
  • J.R. Gillette

    Int. Med.

    (1981)
  • D.G. Dahlin et al.

    J. med. Chem.

    (1982)
  • H. Mukhtar et al.

    Xenobiotica

    (1981)
  • F. Sanger

    Biochem. J.

    (1945)
  • M. Sokolovsky et al.

    J. Am. chem. Soc.

    (1964)
  • H. Zahn et al.

    Z. Naturforsch.

    (1954)
  • Cited by (27)

    • Evaluation of radioiodinated protein conjugates and their potential metabolites containing lysine-urea-glutamate (LuG), PEG and closo-decaborate(2-) as models for targeting astatine-211 to metastatic prostate cancer.

      2021, Nuclear Medicine and Biology
      Citation Excerpt :

      Compounds 9a and 16a, which contain conjugated N-acetyl lysine moieties, were synthesized, radioiodinated and evaluated in vivo. It should be noted that some metabolites of protein conjugates have previously been shown to contain a N-acetyl lysine moiety [39]. The results from that animal study showed a large difference in tumor localization between 16a, which had a prostate cancer-targeting LuG moiety, and 9a, which did not contain a LuG moiety (Fig. 5).

    • Mechanistic role of acyl glucuronides

      2013, Drug-Induced Liver Disease
    View all citing articles on Scopus

    For part VII in the series “Drug-Protein Conjugates” see P. S. Grabowski and B. K. Park, Biochem. Pharmac.33, 3289 (1984).

    Wellcome Senior Lecturer.

    View full text